HEALTHEQUITY (HQY) Insider Notice — 9,000-Share Sale Scheduled
Rhea-AI Filing Summary
Form 144 Notice: This filing reports a proposed sale of 9,000 shares of common stock through Morgan Stanley Smith Barney LLC on 09/19/2025 with an aggregate market value of $860,310.00 and 86,156,334 shares outstanding. The shares were acquired as restricted stock units on 10/01/2023 and paid for on that date. The filer previously sold 970 shares on 07/03/2025 for $97,845.94. The form includes the standard representation that the seller does not possess undisclosed material information and a notice regarding Rule 10b5-1 trading plans. Certain issuer and filer identification fields in the provided text are blank.
Positive
- Compliance disclosure provided: The filer reported the proposed sale and prior sale as required under Rule 144, including a representation about material nonpublic information.
- Securities originated as RSUs: The 9,000 shares were acquired as restricted stock units and paid on the acquisition date, clarifying the nature of the holding.
Negative
- Insider selling activity: The filer plans to sell 9,000 shares and previously sold 970 shares, which may be viewed unfavorably by some investors.
- Missing identification fields in provided text: Several issuer/filer identification items are blank in the supplied extract, limiting attribution from this excerpt alone.
Insights
TL;DR: Routine insider sale of vested RSUs disclosed; no new company fundamentals provided.
The filing documents a planned sale of 9,000 shares previously received as restricted stock units and a recent small sale of 970 shares. This is a standard compliance disclosure that notifies the market of insider selling activity and the method of sale via Morgan Stanley. The filing does not provide issuer financial results, strategic changes, or material nonpublic information. Investors should treat this as a liquidity event by the holder rather than as new operational information.
TL;DR: Filing meets Rule 144 disclosure norms but lacks populated issuer/filer identifiers in the provided extract.
The notice indicates the seller relied on Rule 144 to effect sales of vested RSUs. The document includes the required certification about absence of undisclosed material information and references Rule 10b5-1 planning. However, several issuer/filer identification fields appear blank in the supplied content, which could hinder clear market attribution if absent from the original filing. The disclosure itself is routine and suggests ordinary post-vesting liquidation rather than a governance dispute.